Gabriela Hobbs

Dr. Gabriela Hobbs, a leading hematologist and MPN researcher at Massachusetts General Hospital, shares groundbreaking insights on myeloproliferative neoplasms. She delves into the impressive results from the VERIFY trial on rusfertide, detailing its hematocrit control and safety profile. Dr. Hobbs also discusses the efficacy of ropeginterferon and its advantages over traditional treatments. Additionally, she highlights ongoing clinical trials to watch and emphasizes the pressing need for therapies addressing thrombocytopenia and disease progression.